Advertisement
COCP vs MBIO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COCP is a Hold and MBIO is a Hold.
Momentum Indicator for COCP turns positive, indicating new upward trend
COCP saw its Momentum Indicator move above the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned positive. In 81 of the 94 cases, the stock moved higher in the following days. The odds of a move higher are at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where COCP's RSI Indicator exited the oversold zone, 27 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for COCP just turned positive on October 30, 2026. Looking at past instances where COCP's MACD turned positive, the stock continued to rise in 38 of 48 cases over the following month. The odds of a continued upward trend are 79%.
Following a +9.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where COCP advanced for three days, in 165 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 45 cases where COCP's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.
COCP moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for COCP crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
The 50-day moving average for COCP moved below the 200-day moving average on October 30, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where COCP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
COCP broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for COCP entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 60 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. COCP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.189) is normal, around the industry mean (3.498). P/E Ratio (-1.387) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (45.249) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. COCP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MBIO in +5.73% Uptrend, rising for three consecutive days on November 02, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MBIO advanced for three days, in 147 of 191 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MBIO's RSI Indicator exited the oversold zone, 44 of 59 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on MBIO as a result. In 57 of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for MBIO just turned positive on October 27, 2026. Looking at past instances where MBIO's MACD turned positive, the stock continued to rise in 28 of 40 cases over the following month. The odds of a continued upward trend are 70%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 31 of 31 cases where MBIO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
MBIO broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MBIO entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. MBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.398) is normal, around the industry mean (3.498). P/E Ratio (-0.945) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
COCP | MBIO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 19 | 11 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 86 Overvalued | 88 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 69 | 63 | |
P/E GROWTH RATING 1..100 | 60 | 98 | |
SEASONALITY SCORE 1..100 | 50 | 46 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
COCP's Valuation (86) in the Pharmaceuticals Generic industry is in the same range as MBIO (88) in the Pharmaceuticals Major industry. This means that COCP’s stock grew similarly to MBIO’s over the last 12 months.
COCP's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as MBIO (100) in the Pharmaceuticals Major industry. This means that COCP’s stock grew similarly to MBIO’s over the last 12 months.
MBIO's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as COCP (100) in the Pharmaceuticals Generic industry. This means that MBIO’s stock grew similarly to COCP’s over the last 12 months.
MBIO's Price Growth Rating (63) in the Pharmaceuticals Major industry is in the same range as COCP (69) in the Pharmaceuticals Generic industry. This means that MBIO’s stock grew similarly to COCP’s over the last 12 months.
COCP's P/E Growth Rating (60) in the Pharmaceuticals Generic industry is somewhat better than the same rating for MBIO (98) in the Pharmaceuticals Major industry. This means that COCP’s stock grew somewhat faster than MBIO’s over the last 12 months.
| COCP | MBIO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 84% | 1 day ago 75% |
| Stochastic ODDS (%) | 1 day ago 84% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 86% | 1 day ago 75% |
| MACD ODDS (%) | 1 day ago 79% | 1 day ago 70% |
| TrendWeek ODDS (%) | 1 day ago 84% | 1 day ago 73% |
| TrendMonth ODDS (%) | 1 day ago 87% | 1 day ago 72% |
| Advances ODDS (%) | 3 days ago 83% | 10 days ago 77% |
| Declines ODDS (%) | 1 day ago 84% | 16 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 86% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 86% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
COCP’s FA Score shows that 0 FA rating(s) are green while MBIO’s FA Score has 0 green FA rating(s).
- COCP’s FA Score: 0 green, 5 red.
- MBIO’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
COCP’s TA Score shows that 4 TA indicator(s) are bullish while MBIO’s TA Score has 4 bullish TA indicator(s).
- COCP’s TA Score: 4 bullish, 7 bearish.
- MBIO’s TA Score: 4 bullish, 4 bearish.
Price Growth
COCP (@Biotechnology) experienced а +0.99% price change this week, while MBIO (@Biotechnology) price change was +5.05% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
COCP is expected to report earnings on Nov 13, 2026.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
COCP and
Correlation & Price change
A.I.dvisor tells us that COCP and SRPT have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that COCP and SRPT's prices will move in lockstep.
| Ticker / NAME | Correlation To COCP | 1D Price Change % | ||
|---|---|---|---|---|
| COCP | 100% | -0.97% | ||
| SRPT - COCP | 30% Poorly correlated | +1.58% | ||
| BYSI - COCP | 28% Poorly correlated | +11.06% | ||
| CYTK - COCP | 27% Poorly correlated | +4.18% | ||
| CMMB - COCP | 27% Poorly correlated | +0.37% | ||
| MBIO - COCP | 27% Poorly correlated | -3.06% | ||
More | ||||
MBIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, MBIO has been loosely correlated with MDGL. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MBIO jumps, then MDGL could also see price increases.
| Ticker / NAME | Correlation To MBIO | 1D Price Change % | ||
|---|---|---|---|---|
| MBIO | 100% | -3.06% | ||
| MDGL - MBIO | 50% Loosely correlated | +0.10% | ||
| ORMP - MBIO | 44% Loosely correlated | +4.03% | ||
| AXON - MBIO | 40% Loosely correlated | +4.26% | ||
| SCNI - MBIO | 38% Loosely correlated | +2.85% | ||
| MIRM - MBIO | 34% Loosely correlated | +0.20% | ||
More | ||||